AGTR1 and type 2 diabetes mellitus: Consistent with these findings, treatment with low-dose valsartan, an AT1R antagonist, decreased serum AGE levels in association with reduced oxidative stress generation in type-2 diabetic patients [44] (RAS → AGE-RAGE).